Looking forward to our Alzheimer trial The Eu
Post# of 154983
(Total Views: 624)
Posted On: 07/30/2024 10:02:21 AM
Looking forward to our Alzheimer trial
As of May 15, 2024, Leqembi, an Alzheimer's disease treatment, had global sales of around $19 million in the first three months of 2024, which was almost triple the sales from the final quarter of 2023. However, some say that sales were still below Wall Street estimates and that it's difficult to see how the drug will quickly become the blockbuster Medicare expects it to be.
Some reasons for the slow start in sales include:
Hospitals
Hospitals have taken longer than expected to set up systems to deliver the drug to patients.
Doctors
Some doctors have expressed concerns about the drug's safety and efficacy.
Insurance
Some health insurers have rejected paying for the medication. On average, two-fifths of patients who should be eligible aren't prescribed Leqembi because they can't secure Medicare or other insurance approvals.
Logistics
Leqembi needs to be infused at a specialist center, but three-fifths of patients are receiving treatment at off-site infusion centers.
Despite these challenges, Eisai has set an ambitious goal to hit $364 million in global Leqembi sales for the 2024 fiscal year, which ends in March.
Quote:
The European Medicines Agency has recommended the refusal of the marketing authorisation for Leqembi, a medicine intended for the treatment of Alzheimer’s disease.
As of May 15, 2024, Leqembi, an Alzheimer's disease treatment, had global sales of around $19 million in the first three months of 2024, which was almost triple the sales from the final quarter of 2023. However, some say that sales were still below Wall Street estimates and that it's difficult to see how the drug will quickly become the blockbuster Medicare expects it to be.
Some reasons for the slow start in sales include:
Hospitals
Hospitals have taken longer than expected to set up systems to deliver the drug to patients.
Doctors
Some doctors have expressed concerns about the drug's safety and efficacy.
Insurance
Some health insurers have rejected paying for the medication. On average, two-fifths of patients who should be eligible aren't prescribed Leqembi because they can't secure Medicare or other insurance approvals.
Logistics
Leqembi needs to be infused at a specialist center, but three-fifths of patients are receiving treatment at off-site infusion centers.
Despite these challenges, Eisai has set an ambitious goal to hit $364 million in global Leqembi sales for the 2024 fiscal year, which ends in March.
(4)
(0)CytoDyn Inc (CYDY) Stock Research Links
Whatever happens, we have got
Le-Ron-Li-Mab, and they have not.
Le-Ron-Li-Mab, and they have not.